HX035 / HanX Biopharma - LARVOL DELTA

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting (PRNewswire) - "Hanx Biopharmaceuticals Ltd...highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25–30). The presentations spotlighted novel bispecific antibodies and a CSF-1R inhibitor, underscoring the company's leadership in innovative cancer treatment strategies."

Clinical data • Solid Tumor